Astellas initiates Phase 3 trial of ASP2138 for CLDN18.2-positive gastric cancer, advancing its oncology pipeline
Executive summary: Astellas dosed the first patient in its Phase 3 clinical trial of ASP2138 for Claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. The trial could yield a new treatment option for a difficult-to-treat gastric cancer subset and impact Astellas' oncology revenue prospects.
Who is involved: Astellas Pharma Inc., clinical trial sites, patients with Claudin 18.2-positive gastric cancer, and regulators overseeing the study.
Likely next (inference): The company will continue patient enrollment and expects to report interim efficacy data within the next 12–18 months, followed by potential regulatory submissions if endpoints are met.
On August 24, 2026, Astellas Pharma administered the first dose of ASP2138 in a Phase 3 clinical trial enrolling patients with HER2‑negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma that tests positive for Claudin 18.2. The study is designed to compare the investigational antibody‑drug conjugate against the current standard of care, with primary endpoints focused on overall survival and progression‑free survival, alongside a safety evaluation. This marks Astellas’ latest advancement in its oncology pipeline, positioning the company among several biopharmaceutical firms that have pursued Claudin 18.2‑directed therapies for gastric cancer. The initiation of a pivotal trial underscores the continued interest in targeting Claudin 18.2, a molecule overexpressed in a subset of gastric tumors that has shown promise in earlier‑stage studies. For Astellas, a positive outcome could provide a differentiated treatment option in a disease area where therapeutic choices remain limited, potentially strengthening its competitive stance in the precision oncology market. While the trial’s full enrollment and follow‑up period will take time, interim data readouts are anticipated within the next few years, which will clarify ASP2138’s clinical benefit and inform subsequent regulatory and commercial decisions.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Clinical Dominance (Upside) (30%)
Astellas secures a high-value market share in gastric cancer by significantly outperforming current standards of care.
- Interim data shows statistically significant improvement in progression-free survival
- Lower incidence of Grade 3/4 adverse events compared to competitors
Standard of Care Parity (Base Case) (50%)
ASP2138 enters the market as a viable but non-disruptive third-line treatment option.
- PFS and OS results are non-inferior but not superior to current SoC
- Clinical profile remains consistent with earlier Phase 2 findings
What to watch
- Publication of Phase 2 safety and efficacy data updates (Q4 2026)
- Enrollment speed updates from clinical trial registry (within 180 days)
- Competitor Phase 3 data readouts for other CLDN18.2 targets
Timeline
- — Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (PR Newswire)
Analysis — what this means
Sectors affected
- Gastric adenocarcinoma therapeutics
- Claudin 18.2-targeted oncology
Key entities
Sources
Related cases
- Record low water levels on the Rhine trigger escalating logistics costs for heavy industry
- Hylenr advances to Phase 2 of Lattice-Confinement Fusion reactor development after successful Texas A&M validation
- Grundig unveils a new premium appliance lineup at IFA 2026, marking the start of a deeper strategic partnership phase
- Kazia Therapeutics widens Paxalisib trial to HR+/HER2- breast cancer based on promising preclinical data
- Tezspire’s positive Phase 3 eosinophilic esophagitis data open a new growth avenue for the asthma biologic
- Brii Biosciences shares interim results highlighting HBV cure progress and vaccine advancement backed by a solid cash position